Bladder cancer drug developer BioClin Therapeutics, backed by Novo, has increased its latest funding round from $30m to $50m.

BioClin Therapeutics, a US-based cancer therapy developer that counts pharmaceutical company Novo as an investor, added $20m on Wednesday to a series B round now sized at $50m.

Sectoral Asset Management and Inkef Capital put up the extra cash. Sofinnova Ventures, Ysios Capital, HealthCap, Tekla Capital Management funds and Life Sciences Partners (LSP) had funded the $30m first tranche, which closed in March 2017.

BioClin is working on a monoclonal antibody that will treat metastatic bladder cancer, and the…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?